Process analytical technology (PAT) needs and applications in the bioprocess industry: Review

Markku Känsäkoski, Marika Kurkinen, Niklas von Weymarn, Pentti Niemelä, Peter Neubauer, Esko Juuso, Tero Eerikäinen, Seppo Turunen, Sirkka Aho, Pirkko Suhonen

Research output: Book/ReportReport

Abstract

Process analytical technologies have been applied to manufacturing processes (pulp and paper, chemical and petroleum) for decades. Recently, the US Food and Drug Administration (FDA) has, however, re-defined the phrase and implemented it into an initiative focusing on improving several aspects of the pharmaceutical industry. The European Agency for the Evaluation of Medicinal Products (EMEA), has also been active and formed a PAT team in 2003. The PAT initiative was initially intended for traditional pharmaceutical manufacturers, but the FDA's PAT guidance now clearly states that it applies to all manufacturers of human and veterinary drug products, as well as biologics regulated by the FDA's Center for Drug Evaluation and Research (CDER) and the Center for Veterinary Medicine (CVM). Basically, PAT involves a fundamental shift from testing the quality of the finished drug product, to building quality into products by testing at several intermediate steps. It specifically requires that quantifiable, causal, and predictive relationships be established amongst raw materials, the manufacturing process, and final product quality. It is believed that PAT may not bring dramatic changes overnight, but years from now, it may be seen as an initiative that helped foster a period of innovation, efficiency, and expansion for the biopharmaceutical industry. In this report, the impact and potential effects of PAT on the biotechnological production of pharmaceuticals is assessed. Hence, we define BioPAT as process analytical technologies applied throughout development, scale-up and commercial scale bioprocess-based production of drug substances. In this report, we will focus on what PAT means in practice for the biotechnological manufacture of pharmaceuticals. Besides a regulatory examination, the monitoring methods and technologies available are thoroughly surveyed. These facts are then reflected against the needs for monitoring in bioprocess-based pharmaceutical production.
Original languageEnglish
Place of PublicationEspoo
PublisherVTT Technical Research Centre of Finland
Number of pages100
ISBN (Electronic)951-38-6612-2
Publication statusPublished - 2006
MoE publication typeNot Eligible

Publication series

SeriesVTT Working Papers
Number60

Fingerprint

Industry
Technology
Pharmaceutical Preparations
Veterinary Drugs
Drug Evaluation
Veterinary Medicine
Petroleum
Drug Industry
United States Food and Drug Administration
Biological Products

Keywords

  • process industry
  • process analytical technologies
  • applications
  • bioprocess industry
  • pharmaceutical industry
  • drugs
  • regulations
  • analytical measurements
  • biomanufacturing

Cite this

Känsäkoski, M., Kurkinen, M., von Weymarn, N., Niemelä, P., Neubauer, P., Juuso, E., ... Suhonen, P. (2006). Process analytical technology (PAT) needs and applications in the bioprocess industry: Review. Espoo: VTT Technical Research Centre of Finland. VTT Working Papers, No. 60
Känsäkoski, Markku ; Kurkinen, Marika ; von Weymarn, Niklas ; Niemelä, Pentti ; Neubauer, Peter ; Juuso, Esko ; Eerikäinen, Tero ; Turunen, Seppo ; Aho, Sirkka ; Suhonen, Pirkko. / Process analytical technology (PAT) needs and applications in the bioprocess industry : Review. Espoo : VTT Technical Research Centre of Finland, 2006. 100 p. (VTT Working Papers; No. 60).
@book{d733e315e2474c5296861e4d917ab4c1,
title = "Process analytical technology (PAT) needs and applications in the bioprocess industry: Review",
abstract = "Process analytical technologies have been applied to manufacturing processes (pulp and paper, chemical and petroleum) for decades. Recently, the US Food and Drug Administration (FDA) has, however, re-defined the phrase and implemented it into an initiative focusing on improving several aspects of the pharmaceutical industry. The European Agency for the Evaluation of Medicinal Products (EMEA), has also been active and formed a PAT team in 2003. The PAT initiative was initially intended for traditional pharmaceutical manufacturers, but the FDA's PAT guidance now clearly states that it applies to all manufacturers of human and veterinary drug products, as well as biologics regulated by the FDA's Center for Drug Evaluation and Research (CDER) and the Center for Veterinary Medicine (CVM). Basically, PAT involves a fundamental shift from testing the quality of the finished drug product, to building quality into products by testing at several intermediate steps. It specifically requires that quantifiable, causal, and predictive relationships be established amongst raw materials, the manufacturing process, and final product quality. It is believed that PAT may not bring dramatic changes overnight, but years from now, it may be seen as an initiative that helped foster a period of innovation, efficiency, and expansion for the biopharmaceutical industry. In this report, the impact and potential effects of PAT on the biotechnological production of pharmaceuticals is assessed. Hence, we define BioPAT as process analytical technologies applied throughout development, scale-up and commercial scale bioprocess-based production of drug substances. In this report, we will focus on what PAT means in practice for the biotechnological manufacture of pharmaceuticals. Besides a regulatory examination, the monitoring methods and technologies available are thoroughly surveyed. These facts are then reflected against the needs for monitoring in bioprocess-based pharmaceutical production.",
keywords = "process industry, process analytical technologies, applications, bioprocess industry, pharmaceutical industry, drugs, regulations, analytical measurements, biomanufacturing",
author = "Markku K{\"a}ns{\"a}koski and Marika Kurkinen and {von Weymarn}, Niklas and Pentti Niemel{\"a} and Peter Neubauer and Esko Juuso and Tero Eerik{\"a}inen and Seppo Turunen and Sirkka Aho and Pirkko Suhonen",
year = "2006",
language = "English",
series = "VTT Working Papers",
publisher = "VTT Technical Research Centre of Finland",
number = "60",
address = "Finland",

}

Känsäkoski, M, Kurkinen, M, von Weymarn, N, Niemelä, P, Neubauer, P, Juuso, E, Eerikäinen, T, Turunen, S, Aho, S & Suhonen, P 2006, Process analytical technology (PAT) needs and applications in the bioprocess industry: Review. VTT Working Papers, no. 60, VTT Technical Research Centre of Finland, Espoo.

Process analytical technology (PAT) needs and applications in the bioprocess industry : Review. / Känsäkoski, Markku; Kurkinen, Marika; von Weymarn, Niklas; Niemelä, Pentti; Neubauer, Peter; Juuso, Esko; Eerikäinen, Tero; Turunen, Seppo; Aho, Sirkka; Suhonen, Pirkko.

Espoo : VTT Technical Research Centre of Finland, 2006. 100 p. (VTT Working Papers; No. 60).

Research output: Book/ReportReport

TY - BOOK

T1 - Process analytical technology (PAT) needs and applications in the bioprocess industry

T2 - Review

AU - Känsäkoski, Markku

AU - Kurkinen, Marika

AU - von Weymarn, Niklas

AU - Niemelä, Pentti

AU - Neubauer, Peter

AU - Juuso, Esko

AU - Eerikäinen, Tero

AU - Turunen, Seppo

AU - Aho, Sirkka

AU - Suhonen, Pirkko

PY - 2006

Y1 - 2006

N2 - Process analytical technologies have been applied to manufacturing processes (pulp and paper, chemical and petroleum) for decades. Recently, the US Food and Drug Administration (FDA) has, however, re-defined the phrase and implemented it into an initiative focusing on improving several aspects of the pharmaceutical industry. The European Agency for the Evaluation of Medicinal Products (EMEA), has also been active and formed a PAT team in 2003. The PAT initiative was initially intended for traditional pharmaceutical manufacturers, but the FDA's PAT guidance now clearly states that it applies to all manufacturers of human and veterinary drug products, as well as biologics regulated by the FDA's Center for Drug Evaluation and Research (CDER) and the Center for Veterinary Medicine (CVM). Basically, PAT involves a fundamental shift from testing the quality of the finished drug product, to building quality into products by testing at several intermediate steps. It specifically requires that quantifiable, causal, and predictive relationships be established amongst raw materials, the manufacturing process, and final product quality. It is believed that PAT may not bring dramatic changes overnight, but years from now, it may be seen as an initiative that helped foster a period of innovation, efficiency, and expansion for the biopharmaceutical industry. In this report, the impact and potential effects of PAT on the biotechnological production of pharmaceuticals is assessed. Hence, we define BioPAT as process analytical technologies applied throughout development, scale-up and commercial scale bioprocess-based production of drug substances. In this report, we will focus on what PAT means in practice for the biotechnological manufacture of pharmaceuticals. Besides a regulatory examination, the monitoring methods and technologies available are thoroughly surveyed. These facts are then reflected against the needs for monitoring in bioprocess-based pharmaceutical production.

AB - Process analytical technologies have been applied to manufacturing processes (pulp and paper, chemical and petroleum) for decades. Recently, the US Food and Drug Administration (FDA) has, however, re-defined the phrase and implemented it into an initiative focusing on improving several aspects of the pharmaceutical industry. The European Agency for the Evaluation of Medicinal Products (EMEA), has also been active and formed a PAT team in 2003. The PAT initiative was initially intended for traditional pharmaceutical manufacturers, but the FDA's PAT guidance now clearly states that it applies to all manufacturers of human and veterinary drug products, as well as biologics regulated by the FDA's Center for Drug Evaluation and Research (CDER) and the Center for Veterinary Medicine (CVM). Basically, PAT involves a fundamental shift from testing the quality of the finished drug product, to building quality into products by testing at several intermediate steps. It specifically requires that quantifiable, causal, and predictive relationships be established amongst raw materials, the manufacturing process, and final product quality. It is believed that PAT may not bring dramatic changes overnight, but years from now, it may be seen as an initiative that helped foster a period of innovation, efficiency, and expansion for the biopharmaceutical industry. In this report, the impact and potential effects of PAT on the biotechnological production of pharmaceuticals is assessed. Hence, we define BioPAT as process analytical technologies applied throughout development, scale-up and commercial scale bioprocess-based production of drug substances. In this report, we will focus on what PAT means in practice for the biotechnological manufacture of pharmaceuticals. Besides a regulatory examination, the monitoring methods and technologies available are thoroughly surveyed. These facts are then reflected against the needs for monitoring in bioprocess-based pharmaceutical production.

KW - process industry

KW - process analytical technologies

KW - applications

KW - bioprocess industry

KW - pharmaceutical industry

KW - drugs

KW - regulations

KW - analytical measurements

KW - biomanufacturing

M3 - Report

T3 - VTT Working Papers

BT - Process analytical technology (PAT) needs and applications in the bioprocess industry

PB - VTT Technical Research Centre of Finland

CY - Espoo

ER -

Känsäkoski M, Kurkinen M, von Weymarn N, Niemelä P, Neubauer P, Juuso E et al. Process analytical technology (PAT) needs and applications in the bioprocess industry: Review. Espoo: VTT Technical Research Centre of Finland, 2006. 100 p. (VTT Working Papers; No. 60).